Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

September 13, 2022

Stephen Feldman, a fellow chronic lymphocytic leukemia (CLL) thriver since his diagnosis in 2014, has been playing the guitar since he was a kid. For him, singing and playing music have always provided a soothing and healing experience. Although his consistency with playing has waxed and waned over the
Acalabrutinib plus high-frequency, low-dose subcutaneous rituximab is tolerable and effective. In addition, because it can be administered at home, it is more convenient and can decrease patient infection risk during pandemics. However, while it does control disease, it does not lead to undetectable measurable residual disease (uMRD).